From Breakthrough to Blockbuster: The Business of Biotechnology
Lisa N. Drakeman · Donald L. Drakeman · Nektarios Oraiopoulos
Jul 2022 · Gildan Media · Narrated by Chris Andrew Ciulla
5.0star
1 reviewreport
headphones
Audiobook
7 hr 2 min
Unabridged
family_home
Eligible
info
reportRatings and reviews aren’t verified Learn More
Want a 42 min sample? Listen anytime, even offline.
Add
About this audiobook
Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources.
Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs.
From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.
Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs.
From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.
Ratings and reviews
5.0
1 review
About the author
Donald L. Drakeman was the founding CEO of the US biotech company that pioneered the development of the checkpoint inhibitor cancer treatments recognized in the Nobel Prize for Medicine 2018. He is Distinguished Research Professor in the Program on Constitutional Studies at the University of Notre Dame.
Lisa N. Drakeman was the founding CEO of one of Europe's most successful biotechnology companies. She has been a faculty member at Princeton University and regularly lectures on entrepreneurship at universities in the US and Europe.
Nektarios Oraiopoulos is the director of the MPhil Programme in Strategy, Marketing, & Operations and an associate professor of operations and technology management at the Cambridge Judge Business School of the University of Cambridge.
Chris Andrew Ciulla is a versatile performer with over 50 audiobook credits to his name. In addition to frequent film, television, and on-camera commercial work, Chris has voiced characters for the popular video game titles Fallout 4 and Mafia III, and can be heard in national commercial campaigns.
Rate this audiobook
Tell us what you think.
Listening information
Smartphones and tablets
Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.
Laptops and computers
You can read books purchased on Google Play using your computer's web browser.
